MYCN and acute lymphoblastic leukemia: Since, MYCN overexpression is present in a large group of tumors (4, 9, 44–48), we investigated if MYCN was also associated to immune suppression in different MYCN-expressing cancers (SCLC, RMS, RB, Wilms, AML, T-ALL).